Vaxart VXRT shares are trading higher on Thursday after the company announced additional data from its Hamster Challenge Study of its oral COVID-19 vaccine.
The company saw a significant reduction in lung viral load of 4-5 logs in hamsters that received two oral vaccine doses.
Vaxart Inc is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally.
Vaxart shares traded up 20.52% at $5.55 on Thursday during the time of publication. The stock has a 52-week high of $17.49 and a 52-week low of 27 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
